Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4/A ACHILLION PHARMACEUTICALS INC Form 4/A September 12, 2014 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB Washington, D.C. 20549 Number: Check this box Expires: if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading RA CAPITAL MANAGEMENT, Issuer Symbol LLC **ACHILLION** (Check all applicable) PHARMACEUTICALS INC [ACHN] Director X__ 10% Owner Other (specify Officer (give title (Last) (First) (Middle) 3. Date of Earliest Transaction below) below) (Month/Day/Year) C/O RA CAPITAL 09/10/2014 MANAGEMENT, LLC, 20 PARK PLAZA, SUITE 1200 (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) Form filed by One Reporting Person 09/12/2014 _X_ Form filed by More than One Reporting BOSTON, MA 02116 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. TransactionDisposed of (D) Security (Month/Day/Year) Execution Date, if Securities Ownership (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: anv (Month/Day/Year) (Instr. 8) Owned Direct (D) Following or Indirect Reported (I) (A) Transaction(s) (Instr. 4) or (Instr. 3 and 4) Price Code V Amount (D) Common Stock, \$ 09/10/2014 S 8,600 (1) D 14,695,762 Ι \$0.001 12.7259 par value Common Stock, 49,057 \$ 09/10/2014 S D 14,646,705 Ι

(1)

S

12.6908

14,373,688

Ι

D

\$0.001

par value

09/10/2014

Footnotes

(12) (13)

7. Nature of

Indirect

Beneficial

Ownership

(Instr. 4)

See

See

Footnotes

(12) (13)

3235-0287

January 31,

2005

0.5

1

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4/A

Common Stock, \$0.001 par value			273,017 (2)		\$ 12.7013			See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/10/2014	S	69,833 (<u>3)</u>	D	\$ 12.6288	14,303,855	Ι	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/10/2014	S	121,943 (4)	D	\$ 12.6098	14,181,912	Ι	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/11/2014	S	184,643 (5)	D	\$ 12.4132	13,997,269	Ι	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/11/2014	S	83,560 (6)	D	\$ 12.6238	13,913,709	Ι	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/11/2014	S	531,352 (7)	D	\$ 12.3053	13,382,357	Ι	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/11/2014	S	115,000 (8)	D	\$ 12.3348	13,267,357	Ι	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/11/2014	S	17,357 (9)	D	\$ 12.3248	13,250,000	I	See Footnotes (12) (13)
Common Stock, \$0.001 par value	09/11/2014	S	250,000 (10)	D	\$ 12.35	13,000,000 (11)	Ι	See Footnotes (12) (13)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. oriNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owno Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4/A

Reporting Owners

Reporting Owner Name / Address		Relations	nips				
	Director	10% Owner	Officer	Other			
RA CAPITAL MANAGEMENT, LLC C/O RA CAPITAL MANAGEMENT, LL 20 PARK PLAZA, SUITE 1200 BOSTON, MA 02116	.C	Х					
RA Capital Healthcare Fund LP C/O RA CAPITAL MANAGEMENT, LI 20 PARK PLAZA, SUITE 1200 BOSTON, MA 02116	.C	Х					
Kolchinsky Peter C/O RA CAPITAL MANAGEMENT, LJ 20 PARK PLAZA, SUITE 1200 BOSTON, MA 02116	.C	Х					
Signatures							
Peter Kolchinsky, Manager of RA Capita	09/12/2014						
<u>**</u> Signat	ure of Reporting I	Person			Date		
Peter Kolchinsky, individually					09/12/2014		
<u>**</u> Signal	ure of Reporting I	Person			Date		
Peter Kolchinsky, Manager of RA Capita Capital Healthcare Fund, L.P.	l Manageme	nt, LLC, the	General	Partner of RA	09/12/2014		
<u>**</u> Signal	ure of Reporting I	Person			Date		
Explanation of Responses:							

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) All such shares were sold by RA Capital Healthcare Fund, L.P. (the "Fund").

(2)

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form 4/A

The securities sold include 223,874 shares for the Fund and 49,143 shares for an account owned by Blackwell Partners, LLC (the "Blackwell Account").

- (3) The securities sold include 57,263 shares for the Fund and 12,570 shares for an account owned by the Blackwell Account.
- (4) The securities sold include 99,993 shares for the Fund and 21,950 shares for an account owned by the Blackwell Account.
- (5) The securities sold include 151,407 shares for the Fund and 33,236 shares for an account owned by the Blackwell Account.
- (6) The securities sold include 68,519 shares for the Fund and 15,041 shares for an account owned by the Blackwell Account.
- (7) The securities sold include 435,709 shares for the Fund and 95,643 shares for an account owned by the Blackwell Account.
- (8) The securities sold include 94,299 shares for the Fund and 20,701 shares for an account owned by the Blackwell Account.
- (9) The securities sold include 14,231 shares for the Fund and 3,126 shares for an account owned by the Blackwell Account.
- (10) The securities sold include 205,003 shares for the Fund and 44,997 shares for an account owned by the Blackwell Account.
- (11) Following the transactions set forth on Table I above, 9,982,562 shares are held by the Fund, and 3,017,438 shares are held in the Blackwell Account.

RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Blackwell Account.(12) Peter Kolchinsky is the sole manager of the Adviser. In their respective capacities, each of Mr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities.

Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of their respective pecuniary interests therein. The filing of this

(13) Form 4 shall not be construed as an admission that Mr. Kolchinsky or the Adviser is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of securities reported herein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.